NO20083042L - Indolinforbindelser anvendelige ved behandling av kognitiv svekkelse - Google Patents

Indolinforbindelser anvendelige ved behandling av kognitiv svekkelse

Info

Publication number
NO20083042L
NO20083042L NO20083042A NO20083042A NO20083042L NO 20083042 L NO20083042 L NO 20083042L NO 20083042 A NO20083042 A NO 20083042A NO 20083042 A NO20083042 A NO 20083042A NO 20083042 L NO20083042 L NO 20083042L
Authority
NO
Norway
Prior art keywords
cognitive impairment
treatment
compounds useful
indoline compounds
subject
Prior art date
Application number
NO20083042A
Other languages
English (en)
Norwegian (no)
Inventor
Thomas P Blackburn
Original Assignee
Helicon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helicon Therapeutics Inc filed Critical Helicon Therapeutics Inc
Publication of NO20083042L publication Critical patent/NO20083042L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20083042A 2005-12-09 2008-07-09 Indolinforbindelser anvendelige ved behandling av kognitiv svekkelse NO20083042L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74885105P 2005-12-09 2005-12-09
PCT/US2006/046826 WO2007070362A1 (en) 2005-12-09 2006-12-08 Indolone compounds useful to treat cognitive impairment

Publications (1)

Publication Number Publication Date
NO20083042L true NO20083042L (no) 2008-09-08

Family

ID=37903540

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083042A NO20083042L (no) 2005-12-09 2008-07-09 Indolinforbindelser anvendelige ved behandling av kognitiv svekkelse

Country Status (24)

Country Link
EP (2) EP1957067B1 (de)
JP (1) JP5336194B2 (de)
KR (1) KR20080077646A (de)
CN (1) CN101378750B (de)
AT (1) ATE480234T1 (de)
AU (1) AU2006326665B2 (de)
BG (1) BG110157A (de)
BR (1) BRPI0620034A2 (de)
CA (1) CA2633829A1 (de)
CZ (1) CZ2008423A3 (de)
DE (1) DE602006016849D1 (de)
EA (1) EA200870027A1 (de)
ES (1) ES2349675T3 (de)
HK (1) HK1127736A1 (de)
HR (1) HRP20080254A2 (de)
IL (1) IL192022A0 (de)
IS (1) IS8733A (de)
MX (1) MX2008007377A (de)
NO (1) NO20083042L (de)
PL (1) PL386471A1 (de)
RS (1) RS20080257A (de)
SK (1) SK500262008A3 (de)
WO (1) WO2007070362A1 (de)
ZA (1) ZA200805285B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2011090022A1 (ja) 2010-01-20 2013-05-23 三菱瓦斯化学株式会社 シアン酸エステル化合物およびその硬化物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK69693D0 (da) * 1993-06-14 1993-06-14 Neurosearch As Farven lilla
WO2002060392A2 (en) 2001-01-31 2002-08-08 Synaptic Pharmaceutical Corporation Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
AU2003259074A1 (en) * 2002-08-07 2004-02-25 Synaptic Pharmaceutical Corporation Gal3 antagonists for the treatment of neuropathic pain
WO2004014854A1 (en) * 2002-08-07 2004-02-19 Synaptic Pharmaceutical Corporation 3-imino-2-indolones for the treatment of depression and/or anxiety
AU2003259759A1 (en) * 2002-08-07 2004-02-25 Synaptic Pharmaceutical Corporation Gal3 receptor antagonists for the treatment of affective disorders

Also Published As

Publication number Publication date
KR20080077646A (ko) 2008-08-25
CN101378750B (zh) 2012-07-18
HK1127736A1 (en) 2009-10-02
IL192022A0 (en) 2009-08-03
WO2007070362A1 (en) 2007-06-21
HRP20080254A2 (en) 2008-09-30
RS20080257A (en) 2009-05-06
DE602006016849D1 (de) 2010-10-21
IS8733A (is) 2008-06-20
JP5336194B2 (ja) 2013-11-06
AU2006326665A1 (en) 2007-06-21
ZA200805285B (en) 2009-12-30
AU2006326665B2 (en) 2012-11-15
SK500262008A3 (sk) 2009-03-05
CA2633829A1 (en) 2007-06-21
CZ2008423A3 (cs) 2009-08-05
EA200870027A1 (ru) 2009-12-30
EP1957067B1 (de) 2010-09-08
BRPI0620034A2 (pt) 2011-10-25
PL386471A1 (pl) 2009-04-14
BG110157A (en) 2008-12-30
ATE480234T1 (de) 2010-09-15
EP1957067A1 (de) 2008-08-20
JP2009518431A (ja) 2009-05-07
CN101378750A (zh) 2009-03-04
EP2241316A1 (de) 2010-10-20
ES2349675T3 (es) 2011-01-10
MX2008007377A (es) 2008-10-29

Similar Documents

Publication Publication Date Title
EA200600048A1 (ru) Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
BRPI0607017A2 (pt) métodos e composições para o tratamento de condições relacionadas ao snc
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
WO2006105516A3 (en) Compositions and methods for diagnosing and treating neuropsychiatric disorders
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200702048A1 (ru) Фармакокинетически улучшенные соединения
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
ATE456955T1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
BRPI0410711A (pt) novos compostos
MX2007016469A (es) Metodos de tratamiento utilizando ansamicinas de hidroquinona.
WO2005039504A3 (en) Compounds and methods for treating toll-like receptor 2-related diseases and conditions
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EP1766077A4 (de) Bei manisch-depressiver erkrankung und/oder schwerer depressiver erkrankung unterschiedlich exprimierte gene und wege
EA200900021A1 (ru) Пептидные соединения для лечения рефрактерного эпилептического статуса
EA201000895A1 (ru) Композиции и способы для лечения лизосомных болезней
WO2008155533A3 (en) Phenothiazine compounds for treating mild cognitive impairment
MX2009005351A (es) Compuestos utiles para tratar trastornos neurodegenerativos.
TW200742580A (en) Methods for treating nephrolithiasis
EA200970436A1 (ru) Соединения карбамата для лечения депрессии
HK1083767A1 (en) Combined use of a fibrate and orlistat for the treatment of obesity
NO20083042L (no) Indolinforbindelser anvendelige ved behandling av kognitiv svekkelse
WO2004047727A3 (en) Compositions and methods for diagnosing and treating mood disorders
HU0201394D0 (de)
HK1118007A1 (en) Kim-1 antibodies for treatment of th2-mediated conditions
DE60203026D1 (de) Sulfonylpyridazinone Derivate zur Behandlung von ischämischem Gewebeschaden

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application